Merck, the New Jersey-based drug giant, is spending $1 billion on a new Delaware factory to bring production of its ...

U.S. drugmaker Merck said on Tuesday it is investing $1 billion in a new Delaware plant to expand domestic production as it ...

Merck has initiated construction of a $1 billion, 470,000-square-foot biologics center of excellence in Wilmington, Delaware.

Located at Chestnut Run Innovation & Science Park, the Merck Wilmington Biotech project will comprise laboratory, ...

Merck CEO Robert Davis spoke about the new state-of-the-art biologics center slated to be based in Wilmington, Delaware that ...

According to Merck, the total investment is now expected to be over $1 billion, with 500 full-time jobs and 4,000 ...

Merck announced on Tuesday that it is investing $1 billion in a new Delaware plant to expand domestic production as it ...

The new facility will produce biologic drugs and Keytruda, becoming Merck’s first in-house US site to make the blockbuster ...

Biopharmaceutical giant Merck (NYSE: MRK) has broken ground on a $1 billion pharmaceutical manufacturing facility in ...

The Delaware facility will ensure a domestic supply of biologic drugs including the cancer drug Keytruda.

It will build a Wilmington, Delaware facility dedicated to making its cancer drug, Keytruda, for U.S. patients.

Merck & Co (MSD) has begun construction on a $1bn biologics centre of excellence, Merck Wilmington Biotech, in Delaware, US.